Nyxoah SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: BE0974358906
  • BRU: NYXH
EUR
1.28
0.14 (12.28%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

218.03 k

Shareholding (Jun 2026)

FII

4.54%

Held by 66 FIIs

DII

94.94%

Held by 1 DIIs

Promoter

0.52%

iScoreScore

Dashboard

1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -27.33
2

Flat results in Dec 20

3

Risky -

4

Falling Participation by Institutional Investors

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 119 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.71

stock-summary
Return on Equity

-109.54%

stock-summary
Price to Book

1.43

Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Jun 2026)
Net Profit:
-33 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.28%
0%
-13.28%
6 Months
-52.24%
0%
-52.24%
1 Year
-67.51%
0%
-67.51%
2 Years
-83.11%
0%
-83.11%
3 Years
-81.45%
0%
-81.45%
4 Years
-80.69%
0%
-80.69%
5 Years
-94.79%
0%
-94.79%

Nyxoah SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
88.28%
EBIT Growth (5y)
-203.58%
EBIT to Interest (avg)
-24.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
1.08
Tax Ratio
1.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.57%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.42
EV to EBIT
-1.98
EV to EBITDA
-2.11
EV to Capital Employed
3.76
EV to Sales
10.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-189.79%
ROE (Latest)
-251.07%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bullish
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.09%)

Foreign Institutions

Held by 66 Foreign Institutions (4.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 492.31% vs 62.50% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is -60.19% vs -57.25% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.70",
          "val2": "1.30",
          "chgp": "492.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.80",
          "val2": "-19.10",
          "chgp": "1.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.40",
          "chgp": "25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.20",
          "val2": "0.20",
          "chgp": "-5,700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-33.00",
          "val2": "-20.60",
          "chgp": "-60.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,681.00%",
          "val2": "-14,836.60%",
          "chgp": "1,215.56%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 122.22% vs 4.65% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -52.20% vs -37.04% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.00",
          "val2": "4.50",
          "chgp": "122.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-80.30",
          "val2": "-57.10",
          "chgp": "-40.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.90",
          "val2": "1.90",
          "chgp": "157.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.50",
          "val2": "-0.40",
          "chgp": "475.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-90.10",
          "val2": "-59.20",
          "chgp": "-52.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-8,459.00%",
          "val2": "-13,230.90%",
          "chgp": "477.19%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - YoYstock-summary

Jun'26
Jun'25
Change(%)
Net Sales
7.70
1.30
492.31%
Operating Profit (PBDIT) excl Other Income
-18.80
-19.10
1.57%
Interest
0.50
0.40
25.00%
Exceptional Items
-11.20
0.20
-5,700.00%
Consolidate Net Profit
-33.00
-20.60
-60.19%
Operating Profit Margin (Excl OI)
-2,681.00%
-14,836.60%
1,215.56%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2026 is 492.31% vs 62.50% in Jun 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2026 is -60.19% vs -57.25% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
10.00
4.50
122.22%
Operating Profit (PBDIT) excl Other Income
-80.30
-57.10
-40.63%
Interest
4.90
1.90
157.89%
Exceptional Items
1.50
-0.40
475.00%
Consolidate Net Profit
-90.10
-59.20
-52.20%
Operating Profit Margin (Excl OI)
-8,459.00%
-13,230.90%
477.19%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 122.22% vs 4.65% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -52.20% vs -37.04% in Dec 2024

stock-summaryCompany CV
About Nyxoah SA stock-summary
stock-summary
Nyxoah SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Footer loading